Abdalla Aly, Melissa Lingohr-Smith, Jay Lin, Brian Seal
{"title":"美国肝细胞癌患者的局部治疗模式和医疗经济负担","authors":"Abdalla Aly, Melissa Lingohr-Smith, Jay Lin, Brian Seal","doi":"10.2217/hep-2021-0001","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To examine the locoregional therapy (LRT) patterns and the healthcare economic burden of patients with hepatocellular carcinoma (HCC) in the USA.</p><p><strong>Patients & methods: </strong>Patients with newly diagnosed HCC were identified from the MarketScan<sup>®</sup> databases (1 July 2015-31 May 2018). The LRTs received and all-cause and HCC-related healthcare costs were measured.</p><p><strong>Results: </strong>Among 2101 patients with HCC, most received embolization therapy as their first LRT treatment (57.8%, n = 1215); 17.1% (n = 360) received ablative therapy and 8.7% (n = 182) radiation therapy; 16.4% (n = 344) received multiple LRTs. After patients received their first LRT treatment, total all-cause healthcare costs averaged $20,316 per patient per month; 70.7% ($14,359) were HCC related.</p><p><strong>Conclusion: </strong>Among newly diagnosed HCC patients treated with LRT in the USA, the economic burden is high.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 3","pages":"HEP37"},"PeriodicalIF":1.2000,"publicationDate":"2021-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/00/hep-08-37.PMC8369525.pdf","citationCount":"0","resultStr":"{\"title\":\"Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA.\",\"authors\":\"Abdalla Aly, Melissa Lingohr-Smith, Jay Lin, Brian Seal\",\"doi\":\"10.2217/hep-2021-0001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To examine the locoregional therapy (LRT) patterns and the healthcare economic burden of patients with hepatocellular carcinoma (HCC) in the USA.</p><p><strong>Patients & methods: </strong>Patients with newly diagnosed HCC were identified from the MarketScan<sup>®</sup> databases (1 July 2015-31 May 2018). The LRTs received and all-cause and HCC-related healthcare costs were measured.</p><p><strong>Results: </strong>Among 2101 patients with HCC, most received embolization therapy as their first LRT treatment (57.8%, n = 1215); 17.1% (n = 360) received ablative therapy and 8.7% (n = 182) radiation therapy; 16.4% (n = 344) received multiple LRTs. After patients received their first LRT treatment, total all-cause healthcare costs averaged $20,316 per patient per month; 70.7% ($14,359) were HCC related.</p><p><strong>Conclusion: </strong>Among newly diagnosed HCC patients treated with LRT in the USA, the economic burden is high.</p>\",\"PeriodicalId\":44854,\"journal\":{\"name\":\"Hepatic Oncology\",\"volume\":\"8 3\",\"pages\":\"HEP37\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2021-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/00/hep-08-37.PMC8369525.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/hep-2021-0001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2021-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA.
Aim: To examine the locoregional therapy (LRT) patterns and the healthcare economic burden of patients with hepatocellular carcinoma (HCC) in the USA.
Patients & methods: Patients with newly diagnosed HCC were identified from the MarketScan® databases (1 July 2015-31 May 2018). The LRTs received and all-cause and HCC-related healthcare costs were measured.
Results: Among 2101 patients with HCC, most received embolization therapy as their first LRT treatment (57.8%, n = 1215); 17.1% (n = 360) received ablative therapy and 8.7% (n = 182) radiation therapy; 16.4% (n = 344) received multiple LRTs. After patients received their first LRT treatment, total all-cause healthcare costs averaged $20,316 per patient per month; 70.7% ($14,359) were HCC related.
Conclusion: Among newly diagnosed HCC patients treated with LRT in the USA, the economic burden is high.
期刊介绍：
Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
